“`html
FORZA Trial: Clinical Impact of μQFR, FFR, or OCT Guidance
Background
- The FORZA trial compared the use of FFR or OCT for treatment decisions in patients with intermediate coronary lesions.
- μQFR, a noninvasive method, was evaluated for its clinical impact in the trial.
Methods
- μQFR was assessed at baseline and after PCI.
- Primary endpoint: target vessel failure (TVF) at 3-year follow-up.
Results
- μQFR was evaluated in deferred and treated lesions.
- Post-PCI μQFR was higher in OCT-guided group compared to FFR-guided group.
- TVF rate at 3-year follow-up was comparable for OCT- and FFR-guided treatment decisions.
- Final μQFR was the only predictor of TVF, with μQFR ≤0.89 associated with a 3× increase in TVF.
Conclusions
- OCT-guided PCI resulted in comparable clinical outcomes as FFR-guided PCI.
- μQFR estimated at the end of diagnostic or interventional procedure predicted 3-year TVF.
Registration: ClinicalTrials.gov (Unique identifier: NCT01824030)
“`
